Loading…
Employees: 659
Size ChengDa PharmaCeuticals (301201.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $535M, the 3701st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥23.59 on 6 Nov 2026.
Performance Over six months the shares fell 42.8%, against -10.0% for the median peer and -16.4% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 27.4% over the last twelve months (peer median +6.4%); the operating margin is -9.3% (peer median 10.0%).
Valuation It trades at 5.7× enterprise value to sales against a peer median of 4.0× (7th most expensive of 18).
Capital Return on invested capital runs 7.3 points below its cost of capital (8.9% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥477M | CN¥405M | CN¥333M | CN¥414M | CN¥409M |
| Revenue growth | — | +22% | -20% | +1% | — |
| Gross profit | CN¥201M | CN¥135M | CN¥111M | CN¥162M | CN¥187M |
| EBITDA | n/a | CN¥62.7M | -CN¥4.60M | CN¥103M | CN¥110M |
| Net income | -CN¥41.1M | -CN¥11.9M | -CN¥28.1M | CN¥91.0M | CN¥106M |
| Free cash flow | -CN¥21.7M | -CN¥16.9M | -CN¥227M | CN¥9.23M | -CN¥119M |
| Capital expenditure | CN¥60.9M | CN¥69.0M | CN¥286M | CN¥225M | CN¥206M |
| Total debt | CN¥86.9M | CN¥65.3M | CN¥103M | CN¥31.8M | CN¥1.42M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301201.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -21.0% | -9.3% | 4th lowest of 21 |
| 6-month return | -42.8% | -10.0% | 3rd lowest of 21 |
| Distance from 52-week high | -63.7% | -31.5% | 2nd lowest of 21 |
| Revenue growth (TTM) | +27.4% | +6.4% | 4th highest of 20 |
| Operating margin | -9.3% | 10.0% | 5th lowest of 18 |
| EV / Sales | 5.7× | 4.0× | 7th most expensive of 18 |
| ROIC minus cost of capital | -7.3 pp | -2.6 pp | 6th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ChengDa PharmaCeuticals 301201.SZ | China | $535M | -43% | +27% | -9% | 5.7× | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $533M | -5% | -5% | 7% | 2.7× | 17.7% | +4.4% |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $538M | -22% | -8% | 16% | 2.4× | -5.2% | +9.6% |
| Boryung 003850.KS | South Korea | $531M | -14% | +6% | 6% | 0.7× | -8.9% | +12.6% |
| Zeria Pharmaceutical 4559.T | Japan | $540M | -6% | +12% | 15% | 1.0× | -12.5% | +11.1% |
| Morepen Laboratories MOREPENLAB.NS | India | $529M | +110% | +30% | 11% | 2.2× | n/a | n/a |
| Egetis Therapeutics EGTX.ST | Sweden | $528M | +67% | +39% | -604% | 73.5× | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $544M | -14% | +10% | 39% | 5.3× | -3.9% | +7.6% |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $546M | -44% | +14% | 0% | 1.9× | n/a | n/a |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $525M | +43% | +68% | 37% | 11.3× | 12.9% | +126.7% |
| Entera Bio ENTX | United States | $546M | +142% | -100% | n/a | n/a | n/a | n/a |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $524M | -5% | +18% | 39% | 28.5× | n/a | n/a |
| Newland Pharmaceutical 301277.SZ | China | $523M | -22% | +9% | 11% | 3.9× | 10.2% | +9.1% |
| Capricor Therapeutics CAPR | United States | $523M | -73% | -100% | n/a | n/a | n/a | n/a |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $520M | -20% | -1% | 10% | 2.1× | n/a | n/a |
| Orchid Pharma ORCHPHARMA.NS | India | $551M | +27% | +11% | 0% | 5.5× | n/a | n/a |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $519M | -18% | -4% | 18% | 4.0× | 6.7% | -4.1% |
| Chimin Health Management 603222.SS | China | $553M | -28% | +1% | -28% | 6.8× | n/a | n/a |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $514M | -32% | -4% | -11% | 9.8× | n/a | n/a |
| Ovid Therapeutics OVID | United States | $557M | +2% | -76% | -3,687% | 285.6× | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $510M | +64% | n/a | n/a | n/a | n/a | n/a |